医学
肺癌
免疫疗法
临床试验
模式治疗法
靶向治疗
肿瘤科
围手术期
重症监护医学
癌症
人口
内科学
外科
环境卫生
作者
Nathaniel Deboever,Michael Eisenberg,Alexis P. Chidi,Boris Sepesi
摘要
As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.
科研通智能强力驱动
Strongly Powered by AbleSci AI